Randomised study comparing 48 and 96 weeks peginterferon α-2a therapy in genotype D HBeAg-negative chronic hepatitis B

Pietro Lampertico, Mauro Viganò, Giovan Giuseppe Di Costanzo, Evangelista Sagnelli, Massimo Fasano, Vito Di Marco, Sara Boninsegna, Patrizia Farci, Silvia Fargion, Tiziana Giuberti, Claudio Iannacone, Loredana Regep, Benedetta Massetto, Floriana Facchetti, Massimo Colombo

Research output: Contribution to journalArticlepeer-review

Abstract

Objective: Treatment with peginterferon α-2a (PegIFN) for 48 weeks is the standard of care for selected HBeAg-negative patients chronically infected with hepatitis B virus (HBV), but with limited treatment efficacy. A study was undertaken to investigate whether treatment extension to 96 weeks improves the outcome in this patient population. Methods: 128 HBeAg-negative patients (120 genotype D) were randomised to weekly 180 mg PegIFN for 48 weeks (group A, n=51), 180 μg PegIFN for 48 weeks followed by 135 mg weekly for an additional 48 weeks (group B, n=52) or 180 μg PegIFN plus lamivudine (100 mg/day) for 48 weeks then 135 μg PegIFN for 48 weeks (group C, n=25). Endpoints were alanine aminotransferase normalisation plus HBV DNA

Original languageEnglish
Pages (from-to)290-298
Number of pages9
JournalGut
Volume62
Issue number2
DOIs
Publication statusPublished - Feb 2013

ASJC Scopus subject areas

  • Gastroenterology

Fingerprint Dive into the research topics of 'Randomised study comparing 48 and 96 weeks peginterferon α-2a therapy in genotype D HBeAg-negative chronic hepatitis B'. Together they form a unique fingerprint.

Cite this